Get started
Markets US Stocks Health Technology Pharmaceuticals: Major

Immuron Limited

IMRN NASDAQ
IMRN
Immuron Limited NASDAQ
See more on advanced chartSee more on advanced chart
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
Ideas Financials Technicals

IMRN Depositary Receipt Chart

Ideas

Videos only
Top authors: IMRN
AlenCiken
AlenCiken
Follow Following Unfollow
Immuron’s products found to neutralise Covid-19
IMRN
, 15
Long
IMRN: Immuron’s products found to neutralise Covid-19

Immuron’s commercially available products found to neutralise COVID-19 during in vitro research smallcaps.com.au Immuron’s commercially available products found to neutralise COVID-19 during in vitro research By Lorna Nicholas - July 21, 2020 Immuron ASX IMC NASDAQ IMRN SARS-CoV-2...

NMRC received guidance from the FDA
IMRN
, 60
IMRN: NMRC received guidance from the FDA

NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC -Two human phase II clinical trials to be conducted in 2021 -One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis -The second trial will focus on ETEC...

IMRN
IMRN
, 60
Long
IMRN: IMRN

Looks like a big wave is coming, announced new partnership what do you guys think?

NMRC Requests Meeting with FDA for Guidance on two Phase 2 trial
IMRN
, 60
IMRN: NMRC Requests Meeting with FDA for Guidance on two Phase 2 trial

US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021 One trial will focus on the ability of the...

rwerew
IMRN
, 15
IMRN: rwerew

ewrrwer

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Breaking news